Microbiota Clinical Trial
— FLORABIOTICOfficial title:
Effect of a Probiotic Consumption on Gastrointestinal Symptoms in Adults Men and Women (FLORABIOTIC REFUERZO).
The goal of this randomized clinical trial is to evaluate the effect on the microbiota and the reduction in the number and/or intensity of symptoms of gastrointestinal discomfort of consuming a probiotic or placebo for 6 weeks in adult women and men. The main questions to answer are: 1. To study changes in the alpha diversity of the microbiota. 2. To evaluate changes in the salivary cortisol. For this purpose, a randomized, double blind crossover study has been designed. Target sample size is 30 subjects. Participants will be allocated in two groups for 16 weeks (6 weeks consuming one of the products + 4 weeks wash-out period + 6 weeks consuming the other product). - Group 1 (n=15): 6 weeks daily consumption of one probiotic capsule + 4 weeks wash-out period+ 6 weeks daily consumption of one placebo capsule. - Group 2 (n=15): 6 weeks daily consumption of one placebo capsule + 4 weeks wash-out period+ 6 weeks daily consumption of one probiotic capsule.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | July 30, 2024 |
Est. primary completion date | June 30, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Volunteers of both sexes aged between 18 and 65 years old. - Volunteers with a body mass index between 18.5 and 30 kg/m2. - Present some type of discomfort/discomfort at gastrointestinal levels without having a specific diagnosis.The gastrointestinal symptoms rating scale will be used to more objectively detect these symptoms. A score between 3 and 5 in any of the symptoms will be an inclusion criterion. - Present a stable weight (+/- 3 kg) in the last three months prior to the start of the study. - Subjects must be able to understand and be willing to sign the informed consent, and must comply with all study procedures and requirements. Exclusion Criteria: - Subjects with relevant functional or structural anomalies of the digestive system, such as malformations, angiodysplasias, active peptic ulcers, chronic inflammatory or malabsorption diseases, hiatal hernia, reflux with medication, helicobacter pylori, celiac disease and other diagnosed intolerances, etc. - Subjects with surgical interventions with permanent consequences in the digestive system (for example, gastroduodenostomy). - Subjects following treatments that alter gastrointestinal function, either chronically or occasionally. - Subjects who are being treated with antibiotics (in order to participate, they do not have to have taken antibiotics during the two months prior to the baseline visit). - Subjects with any type of cancer or undergoing treatment for it, or with less than 5 years since its eradication. - Subjects with any liver disease (may participate with non-alcoholic fatty liver disease). - Subjects with allergy to any component of the product under study. - Subjects with a high alcohol intake, more than 14 units/day (women) and 20 units/day (men). - Pregnant or breastfeeding women. - Subjects who present some type of cognitive and/or psychological impediment. - Subjects in whom poor collaboration is expected or with difficulties in following the study procedures. - Subjects who work with shift changes that include nights. - Subjects who follow any type of supplementation that interferes with the study (example: other probiotics). - Subjects who are immersed in a significant lifestyle change. |
Country | Name | City | State |
---|---|---|---|
Spain | Centre for Nutrition Research | Pamplona | Navarre |
Lead Sponsor | Collaborator |
---|---|
Clinica Universidad de Navarra, Universidad de Navarra |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fecal microbiota | Fecal microbiota of participants will be analyzed by bacterial 16S gene sequencing technology. | Clinical Investigation Days 1, 2, 3 and 4. | |
Secondary | Salivary cortisol | Cortisol levels will be taken by SalivetteĀ®- Cortisol kit and analyzed by electrochemiluminescence immunoassay and reported in ug/dL. | Clinical Investigation Days 1, 2, 3 and 4 (at wake up in the morning, and at the same time in each Clinical investigation days). | |
Secondary | Body weight | Weight of participants will be measured by bioimpedance and reported in kg | Clinical Investigation Days 1, 2, 3 and 4 | |
Secondary | Height | Height of participants will be measured by stadiometer and reported in m. | Clinical Investigation Day 1 | |
Secondary | Body mass index | Body mass index will be calculated as follows: weight (kg)/ height (cm)2. | Clinical Investigation Days 1, 2, 3 and 4 | |
Secondary | Body fat percentage | Body fat of participants will be analyzed by bioimpedance and reported in percentage and kilograms. | Clinical Investigation Days 1, 2, 3 and 4 | |
Secondary | Body muscle mass | Body muscle mass of participants will be analyzed by bioimpedance and reported in kilograms. | Clinical Investigation Days 1, 2, 3 and 4 | |
Secondary | Body lean mass | Body lean mass of participants will be analyzed by bioimpedance and reported in kilograms. | Clinical Investigation Days 1, 2, 3 and 4 | |
Secondary | Body water mass | Body water mass of participants will be analyzed by bioimpedance and reported in kilograms. | Clinical Investigation Days 1, 2, 3 and 4 | |
Secondary | Body bone mass | Body bone mass of participants will be analyzed by bioimpedance and reported in kilograms. | Clinical Investigation Days 1, 2, 3 and 4 | |
Secondary | Gastrointestinal symptoms | Gastrointestinal symptoms will be registrated through 15 items likert questionnaire; gastrointestinal symptoms rating scale questionnaire. | Clinical Investigation Days 1, 2, 3 and 4 | |
Secondary | Dietary intake | Dietary intake will be analysed by food frequency questionnaire. | Clinical Investigation Days 1, 2, 3 and 4 | |
Secondary | Physical activity | Physical activity will be evaluated by the reduced version of the International Physical Activity Questionnaire (IPAQ). | Clinical Investigation Days 1, 2, 3 and 4 | |
Secondary | Adherence to capsule consumption | Adherence will be assessed using the capsule consumption record form. | Clinical Investigation Days 1, 2, 3 and 4 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03239197 -
Project SHARE (motherS Have All the Right microbEs)
|
N/A | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Recruiting |
NCT06144905 -
Norwegian Microbiota Study in Anorexia Nervosa
|
||
Completed |
NCT05864352 -
The Role of Dietary Titanium Dioxide on the Human Gut Microbiome and Health
|
||
Recruiting |
NCT04138979 -
Intestinal Microbiota of Breast Cancer Patients Undergoing Chemotherapy
|
||
Recruiting |
NCT04132713 -
Study on Skin Microbiome of HFS
|
||
Completed |
NCT05726435 -
Effects of Soluble Dietary Fiber on Sport Efficiency and Fatigue Delay in Top Basketball Players
|
N/A | |
Recruiting |
NCT02695784 -
Probiotics After Discharge
|
Phase 4 | |
Completed |
NCT03543891 -
Intestinal Microbiota and Thyroid Cancer
|
||
Completed |
NCT05242913 -
Effects of Resistant Potato Starch on the Gut Microbiota
|
N/A | |
Recruiting |
NCT04200521 -
The Effect of Bariatric Procedures on Gut Microbiota in Obese Individuals in United Arab Emirates and Lebanon
|
||
Recruiting |
NCT05891977 -
Effect of Tomato Paste Consumption on the Microbiota-gut-brain Axis in Healthy Adults
|
N/A | |
Completed |
NCT02988349 -
Ecological Effect of Arginine Dentifrice on Oral Microbiota
|
N/A | |
Completed |
NCT05352724 -
Clinical Trial to Evaluate the Efficacy of a Sport Drink After High-intensity Aerobic Exercise
|
N/A | |
Completed |
NCT04674839 -
The Impact of MS-20 on Gut Microbiota Composition in Adult Individuals
|
N/A | |
Completed |
NCT03754504 -
Effects of Cranberry Powder Supplements on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Completed |
NCT05394948 -
Circular Economy and the Design of Healthy and Sustainable Food and Ingredients
|
N/A | |
Terminated |
NCT03752372 -
Microbiome Alterations in IL10RA-deficient Patients After HSCT
|
||
Completed |
NCT05974124 -
Effectiveness of Ophthalmic Antiseptic Preparations
|
N/A | |
Recruiting |
NCT02005003 -
Cognitive and Metabolic Effects of a Probiotic Supplement
|
N/A |